CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
DualTPharma is developing targeted oral pharmaceuticals for personalized cancer treatment using non-pathogenic Clostridium bacteria as a delivery vehicle. The project aims to enhance immunotherapy efficacy by creating a new class of dual drugs while building expertise in bacterial genetics.
DualTPharma (DTP) is a new venture developing a highly-potent and proprietary line of targeted pharmaceuticals for personalised cancer treatment.
Our mission is to broaden our current pipeline by developing a new class of dual drugs for cancer treatment which are well tolerated and can be taken orally.
This novel solution comprises the application of non-pathogenic Clostridium bacteria as a novel tumour delivery vehicle for anti-cancer drugs to increase immunotherapy efficacy.
Even though DTP ha…
EXOMNIS BIOTECH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
